|
1
|
Corr BR, Erickson BK, Barber EL, Fisher CM
and Slomovitz B: Advances in the management of endometrial cancer.
BMJ. 388:e0809782025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Giaquinto AN and Jemal A:
Cancer statistics, 2024. CA Cancer J Clin. 74:12–49.
2024.PubMed/NCBI
|
|
3
|
Bokhman JV: Two pathogenetic types of
endometrial carcinoma. Gynecol Oncol. 15:101983. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kandoth C, Schultz N, Cherniack AD, Akbani
R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, et al:
Integrated genomic characterization of endometrial carcinoma.
Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mittica G, Ghisoni E, Giannone G, Aglietta
M, Genta S and Valarega G: Checkpoint inhibitors in endometrial
cancer: Preclinical rationale and clinical activity. Oncotarget.
8:90532–90544. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Key TJ and Pike MC: The Dose-effect
relationship between ‘unopposed’ oestrogens and endometrial mitotic
rate: Its central role in explaining and predicting endometrial
cancer risk. Br J Cancer. 57:205–212. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Klinge CM: miRNAs regulated by estrogens,
tamoxifen, and endocrine disruptors and their downstream gene
targets. Mol Cell Endocrinol. 418:273–297. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chan KKL, Siu MKY, Jiang YX, Wang JJ, Wang
Y, Leung THY, Liu SS, Cheung ANY and Ngan HYS: Differential
expression of estrogen receptor subtypes and variants in ovarian
cancer: Effects on cell invasion, proliferation and prognosis. BMC
Cancer. 17:6062017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jameera Begam A, Jubie S and Nanjan MJ:
Estrogen receptor agonists/antagonists in breast cancer therapy: A
critical review. Bio Org Chem. 71:257–274. 2017.PubMed/NCBI
|
|
10
|
Hu G, Zhang J, Zhou X, Liu J, Wang Q and
Zhang B: Roles of estrogen receptor α and β in the regulation of
proliferation in endometrial carcinoma. Pathol Res Pract.
216:1531492020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Backes FJ, Walker CJ, Goodfellow P, Hade
EM, Agarwal G, Mutch D, Cohn DE and Suarez AA: Estrogen
receptor-alpha is a predictive biomarker in endometrioid
endometrial cancer. Gynecol Oncol. 141:312–317. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ning C, Xie B, Zhang L, Li C, Shan W, Yang
B, Luo X, Gu C, He Q, Jin H, et al: Infiltrating macrophages induce
ERα expression through an IL17A-mediated epigenetic mechanism to
sensitize endometrial cancer cells to estrogen. Cancer Res.
76:1354–1366. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wik E, Ræder MB, Krakstad C, Trovik J,
Birkeland E, Hoivik EA, Mjos S, Werner HMJ, Mannelqvist M,
Stefansson IM, et al: Lack of estrogen receptor-α is associated
with epithelial-mesenchymal transition and PI3K alterations in
endometrial carcinoma. Clin Cancer Res. 19:1094–1105. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sasaki M, Kotcherguina L, Dharia A,
Fujimoto S and Dahiya R: Cytosine-phosphoguanine methylation of
estrogen receptors in endometrial cancer. Cancer Res. 15:3262–3266.
2001.PubMed/NCBI
|
|
15
|
Shiozawa T, Itoh K, Horiuchi A, Konishi I,
Fujii S and Nikaido T: Down-regulation of estrogen receptor by the
methylation of the estrogen receptor gene in endometrial carcinoma.
Anticancer Res. 22:139–143. 2002.PubMed/NCBI
|
|
16
|
Navari JR, Roland PY, Keh P, Salvesen HB,
Akslen LA, Iversen OE, Das S, Kothari R, Howey S and Phillips B:
Loss of estrogen receptor (ER) expression in endometrial tumors is
not associated with de novo methylation of the 5′end of the ER
gene. Clin Cancer Res. 6:4026–4032. 2000.PubMed/NCBI
|
|
17
|
Chavez JA, Wei L, Suarez AA, Parwani AV
and Li Z: Clinicopathologic characteristics, tumor infiltrating
lymphocytes and programmed cell death ligand-1 expression in 162
endometrial carcinomas with deficient mismatch repair function. Int
J Gynecol Cancer. 29:113–118. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
De Jong RA, Leffers N, Boezen HM, Ten Hoor
KA, Van der Zee AG, Hollema H and Nijman HW: Presence of
Tumor-infiltrating Lymphocytes is an independent prognostic factor
in type I and II endometrial cancer. Gynecol Oncol. 114:105–110.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Čermáková P, Melichar B, Tomšová M, Zoul
Z, Kalábová H, Spaček J and Doležel M: Prognostic significance of
CD3+ tumorinfiltrating lymphocytes in patients with endometrial
carcinoma. Anticancer Res. 34:5555–5561. 2014.PubMed/NCBI
|
|
20
|
Jung IK, Kim SS, Suh DS, Kim KH, Lee CH
and Yoon MS: Tumor-infiltration of T-lymphocytes is inversely
correlated with clinicopathologic factors in endometrial
adenocarcinoma. Obstet Gynecol Sci. 57:266–273. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo F, Dong Y, Tan Q, Kong J and Yu B:
Tissue infiltrating immune cells as prognostic biomarkers in
endometrial cancer: A Meta-analysis. Dis Markers. 2020:18057642020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Talhouk A, Derocher H, Schmidt P, Leung S,
Milne K, Gilks CB, Anglesio MS, Nelson BH and McAlpine JN:
Molecular subtype not immune response drives outcomes in
endometrial carcinoma. Clin Cancer Res. 25:2537–2548. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Willvonseder B, Stögbauer F, Steiger K,
Jesinghaus M, Kuhn PH, Brambs C, Engel J, Bronger H, Schmidt GP,
Haller B, et al: The immunologic tumor microenvironment in
endometrioid endometrial cancer in the morphomolecular context:
Mutual correlations and prognostic impact depending on molecular
alterations. Cancer Immunol Immunother. 70:1679–1689. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Howitt BE, Shukla SA, Sholl LM,
Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC,
D'Andrea AD, Wu CJ, et al: Association of polymerase e-Mutated and
Microsatellite-instable endometrial cancers with neoantigen load,
number of Tumor-infiltrating lymphocytes, and expression of PD-1
and PD-L1. JAMA Oncol. 1:1319–1323. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Adurthi S, Kumar MM, Vinodkumar HS,
Mukherjee G, Krishnamurthy H, Acharya KK, Bafna UD, Uma DK,
Abhishekh B, Krishna S, et al: Oestrogen Receptor-α binds the FOXP3
promoter and modulates regulatory T-cell function in human cervical
cancer. Sci Rep. 7:72892017. View Article : Google Scholar
|
|
26
|
Stender JD, Kim K, Charn TH, Komm B, Chang
KCN, Kraus WL, Benner C, Glass CK and Katzenellenbogen BS:
Genome-wide analysis of estrogen receptor alpha DNA binding and
tethering mechanisms identifies Runx1 as a novel tethering factor
in receptor-mediated transcriptional activation. Mol Cell Biol.
30:3943–3955. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jedryka M, Chrobak A, Chelmonska-Soyta A,
Fijałkowska D and Matkowski R: Decreased expression of estrogen
receptors alpha and beta in peripheral blood lymphocytes from the
endometrial cancer patients and women with endometriosis. Eur J
Gynaecol Oncol. 42:375–379. 2020.
|
|
28
|
Laczmanska I, Michalowska D, Jedryka M,
Blomka D, Semeniuk M, Czykalko E, Abrahamowska M, Mlynarczykowska
P, Chrusciel A, Pawlak I and Maciejczyk A: Fast and reliable sanger
POLE sequencing protocol in FFPE tissues of endometrial cancer.
Pathol Res Pract. 242:1543152023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Amant F, Mirza MR, Koskas M and Creutzberg
CL: Cancer of the corpus uteri. Int J Gynecol Obstet. 143 (Suppl
2):S37–S50. 2018. View Article : Google Scholar
|
|
30
|
Concin N, Matias-Guiu X, Vergote I, Cibula
D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti
A, et al: ESGO/ESTRO/ESP guidelines for the management of patients
with endometrial carcinoma. Int J Gynecol Cancer. 31:12–39. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pascual-Garcia M, Bertolo C, Nieto JC,
Serrat N, Espinosa I, D'Angelo E, Munoz R, Rovira R, Vidal S and
Prat J: CD8 Down-regulation on cytotoxic T lymphocytes of patients
with endometrioid endometrial carcinomas. Hum Pathol. 56:180–188.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dong D, Lei H, Liu D, Bai H, Yang Y, Tang
B, Li K, Liu J, Xu G and Xiao X: POLE and mismatch repair status,
checkpoint proteins and tumor-infiltrating lymphocytes in
combination, and tumor differentiation: Identify endometrial
cancers for immunotherapy. Front Oncol. 11:6400182021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mendiola M, Pellinen T, Ramon-Patino JL,
Berjon A, Bruck O, Heredia-Soto V, Turrki R, Escudero J, Hemmes A,
Garcia de la Calle LE, et al: Prognostic implications of
tumor-infiltrating T cells in early-stageendometrial cancer. Mod
Pathol. 35:256–265. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Osorio JC and Zamarin D: Beyond T cells:
IgA incites immune recognition in endometrial cancer. Cancer Res.
82:766–768. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mandal G, Biswas S, Anadon CM, Yu X,
Gatenbee CD, Prabhakaran S, Payne KK, Chaurio RA, Martin A,
Innamarato P, et al: IgA-dominated humoral immune responses govern
patients' outcome in endometrial cancer. Cancer Res. 82:859–871.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ge Y, Ni X, Li J, Ye M and Jin X: Roles of
estrogen receptor α in endometrial carcinoma (review). Oncol Lett.
26:5302023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kreizman-Shefer H, Pricop J, Goldman S,
Elmalah I and Shalev E: Distributions of estrogen and progesterone
receptor isoforms in endometrial cancer. Diagn Pathol. 9:772014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Den Boon JA, Pyeon D, Wang SS, Horswill M,
Schiffman M, Sherman M, Zuna RE, Wang Z, Hewitt SM, Pearson R, et
al: Molecular transitions from papillomavirus infection to cervical
precancer and cancer: Role of stromal estrogen receptor signaling.
Proc Natl Acad Sci. 112:E3255–E3264. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rae JM and Lippman ME: The role of
estrogen receptor signaling in suppressing the immune response to
cancer. J Clin Invest. 131:e1554762021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chakraborty B, Byemerwa J, Shepherd J,
Haines CN, Baldi R, Gong W, Liu W, Mukherjee D, Artham S, Lim F, et
al: Inhibition of estrogen signaling in myeloid cells increases
tumor immunity in melanoma. J Clin Invest. 131:e1513472021.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guo YE, Liu Y, Zhang W, Luo H, Shu P, Chen
G and Li Y: The clinicopathological characteristics, prognosis and
immune microenvironment mapping in MSI-H/MMR-D endometrial
carcinomas. Discov Oncol. 13:122022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
van der Woude H, Hally KE, Currie MJ,
Gasser O and Henry CE: Importance of the endometrial immune
environment in endometrial cancer and associated therapies. Front
Oncol. 12:9752012022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Siiteri PK: Review of studies on estrogen
biosynthesis in the human. Cancer Res. 42 (8 Suppl):3269S–3273S.
1982.PubMed/NCBI
|
|
44
|
Vincze B, Kapuvári B, Udvarhelyi N,
Horváth Z, Mátrai Z, Czeyda-Pommersheim F, Kohalmy K, Kovacs J,
Boldizsar M, Lang I, et al: Serum estrone concentration, estrone
sulfate/estrone ratio and BMI are associated with human epidermal
growth factor receptor 2 and progesterone receptor status in
postmenopausal primary breast cancer patients suffering invasive
ductal carcinoma. Springerplus. 4:3872015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Busch EL, Crous-Bou M, Prescott J, Chen
MM, Downing MJ, Rosner BA, Mutter GL and De Vivo I: Endometrial
cancer risk factors, hormone receptors, and mortality prediction.
Cancer Epidemiol Biomarkers Prev. 26:727–735. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dyck L, Prendeville H, Raverdeau M, Wilk
MM, Loftus RM, Douglas A, McCormack J, Moran B, Wilkinson M, Mills
EL, et al: Suppressive effects of the obese tumor microenvironment
on CD8 T cell infiltration and effector function. J Exp Med.
219:e202100422022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Naqvi A, MacKintosh ML, Derbyshire AE,
Tsakiroglou AM, Walker TDJ, McVey RJ, Bolton J, Fergie M, Bagley S,
Ashton G, et al: The impact of obesity and bariatric surgery on the
immune microenvironment of the endometrium. Int J Obes. 46:605–612.
2022. View Article : Google Scholar : PubMed/NCBI
|
